Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelly A McNeil

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 21, 2017
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trialMay S ElSherif, Catherine Brown, Donna MacKinnon-Cameron, et al.
BMJ Open Respiratory Research|March 20, 2020
Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015Jason LeBlanc, May ElSherif, Lingyun Ye, et al.
The Journal of Infectious Diseases|July 30, 2025
Incidence of Respiratory Syncytial Virus-Associated Hospitalization Among Adults in Ontario, Canada, 2017-2019Sarah A Buchan, Jenna Alessandrini, Samantha S M Drover, et al.
Vaccine|July 27, 2019
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)Jason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Cancer|February 2, 2019
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trialPeter Vink, Ignacio Delgado Mingorance, Constanza Maximiano Alonso, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Vaccine|May 31, 2017
Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network studyJason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Vaccine|March 22, 2022
Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assayJason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Human Vaccines & Immunotherapeutics|June 20, 2019
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trialsLidia Oostvogels, Thomas C Heineman, Robert W Johnson, et al.
Vaccine|September 11, 2023
Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)Henrique Pott, Melissa K Andrew, Zachary Shaffelburg, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 21, 2017
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trialMay S ElSherif, Catherine Brown, Donna MacKinnon-Cameron, et al.
BMJ Open Respiratory Research|March 20, 2020
Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015Jason LeBlanc, May ElSherif, Lingyun Ye, et al.
The Journal of Infectious Diseases|July 30, 2025
Incidence of Respiratory Syncytial Virus-Associated Hospitalization Among Adults in Ontario, Canada, 2017-2019Sarah A Buchan, Jenna Alessandrini, Samantha S M Drover, et al.
Vaccine|July 27, 2019
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)Jason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Cancer|February 2, 2019
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trialPeter Vink, Ignacio Delgado Mingorance, Constanza Maximiano Alonso, et al.
Open Forum Infectious Diseases|June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 YearsRafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
Vaccine|May 31, 2017
Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network studyJason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Vaccine|March 22, 2022
Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assayJason J LeBlanc, May ElSherif, Lingyun Ye, et al.
Human Vaccines & Immunotherapeutics|June 20, 2019
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trialsLidia Oostvogels, Thomas C Heineman, Robert W Johnson, et al.
Vaccine|September 11, 2023
Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)Henrique Pott, Melissa K Andrew, Zachary Shaffelburg, et al.
Pageof 11